May 6, 2010: The Whittemore Peterson Institute's study of XMRV with UK ME patients is now closed. We want to thank everyone who volunteered for the study to donate blood samples to the institute for research on XMRV incidence in ME/CFS. The patients that have been selected have been contacted by International Phlebotomy Services. If you have not been contacted we are sorry but you will not be part of this study and have been put on a waiting list for future studies. We encourage you to check the websites for announcements of additional studies but do not anticipate additional studies for at least 6 months.

New treatment strategies for immune modulation and antiviral strategies have been successfully developed for chronic inflammatory disease over the last decade. Each of these drugs has had to undergo extensive investigation before obtaining approval for general use.

A critical need is sub grouping the spectrum of neuro-immune disease in order to stratify patients according to the appropriate therapy. The current translational and clinical research studies at WPI have clinical trials as endpoints. While WPI currently has no open clinical trials, when trials are initiated they will offer patients the opportunity to participate in clinical trials that are designed to test the effectiveness of new forms of therapy. Clinical trials are voluntary, and our team will only involve patients who are entirely comfortable with the process.

No WPI staff have any financial interests or holdings in the various pharmaceutical companies who produce drugs used to treat chronic diseases.

For more information, please contact:

Research Program Coordinator
Whittemore Peterson Institute
6600 N. Wingfield Parkway
Sparks, NV 89436
patientinfo@wpinstitute.org